Chronic Treatment with Talipexole Dihydrochloride on Abnormal Involuntary Movement in Humans
- 1 June 1990
- journal article
- research article
- Published by Wolters Kluwer Health in Clinical Neuropharmacology
- Vol. 13 (3) , 259-263
- https://doi.org/10.1097/00002826-199006000-00010
Abstract
Two cases of severe dystonia and dyskinesia were treated with talipexole, a dopamine autoreceptor agonist, and the metabolites of dopamine, norepinephrine, and serotonin in cerebrospinal fluid (CSF) were determined. Despite significant reductions in these metabolites in CSF, behavioral amelioration of these cases could not be observed. The present findings argue for further studies to explore the clinical usefulness of dopaminergic agonists such as talipexole.This publication has 5 references indexed in Scilit:
- Treatment of tardive dyskinesia with ceruletideProgress in Neuro-Psychopharmacology and Biological Psychiatry, 1988
- The dopamine autoreceptor agonist B-HT 920 inhibits in vivo dopamine release into the cerebroventricular system of catsEuropean Journal of Pharmacology, 1987
- Effects of B‐HT 920 and B‐HT 933 on Dopamine and Noradrenaline Autoreceptors in the Rat BrainActa Pharmacologica et Toxicologica, 1983
- Dopamine released from dendrites in the substantia nigra controls the nigral and striatal release of serotoninBrain Research, 1980
- Effects of GABA, dopamine, and substance P on the release of newly synthesized 3H-5-hydroxytryptamine from rat substantia nigra in vitroNaunyn-Schmiedebergs Archiv für experimentelle Pathologie und Pharmakologie, 1978